drugset

drugset / Trial / NCT02809534

A Study of Anlotinib in Patients With Hepatocellular Carcinoma

NCT02809534 ↗

Phase 2 Unknown 60 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

To assess the primary effects and safety of Anlotinib with placebo in patients with Hepatocellular Carcinoma(HCC).

Timeline

Start: 2016-09
Primary completion: 2017-12
Completion: 2017-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	—	Oral

Indications